Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Receivables - Net data on file, last reported at $39.0 million in Q1 2026.

• Quarterly Receivables - Net fell 4.41% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.0 million (down 4.41% YoY) and the FY2025 annual result came in at $98.0 million, up 15.29% from the prior year.
• Receivables - Net eased to $39.0 million in Q1 2026 per RARE's latest filing, from $98.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $124.5 million in Q2 2025 and bottomed at $15.2 million in Q3 2022.
• The 5-year median for Receivables - Net is $73.4 million (2023), against an average of $67.3 million.
• The widest annual swing landed in 2023, when Receivables - Net surged 421.47%; it then plunged 59.3% in 2025.
• Tracing RARE's Receivables - Net over 5 years: stood at $40.4 million in 2022, then jumped by 81.46% to $73.4 million in 2023, then grew by 15.82% to $85.0 million in 2024, then advanced by 15.29% to $98.0 million in 2025, then plunged by 60.2% to $39.0 million in 2026.
• Per Business Quant, the three latest RARE Receivables - Net figures stand at $39.0 million (Q1 2026), $98.0 million (Q4 2025), and $112.5 million (Q3 2025).

Peer Comparison